In October 2017 Mission Bio announced that it had completed a $10 million Series A financing round. The financing will support the launch of the firm's single-cell DNA analysis platform, Tapestri. Mayfield Fund, a Silicon Valley venture capital firm, led the round.
On December 13, 2018, Mission Bio announced it had completed its $30 million Series B round. Investors include Agilent Technologies, Cota Capital, LAM Capital, and Mayfield, bringing the total amount raised by the company to more than $50 million.
Tapestri is able to identify single-nucleotide variants (SNVs) and indels, two types of genetic variants that are relevant to precision medicine. Tapestri is a targeted single-cell DNA sequencing platform, enabling detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables, and analysis software, which integrate with existing NGS workflows.
Mission Bio, Inc. announces the publication of a study demonstrating Tapestri®
Mission Bio Launches TapestriR Designer, the First Automated On-Demand Cloud Tool for Targeted Single-Cell DNA Custom Panels
Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, today announced the launch of Tapestri Designer, the first-ever automated, cloud-based tool for designing targeted single-cell DNA custom panels.
Mission Bio, Inc. announced it raised $30 million in Series B funding from Agilent Technologies (NYSE:)
CSO and Co-founder
Documentaries, videos and podcasts
- Mayfield FundMayfield Fund is a venture capital firm which specializes in seed, early stage, later stage and growth investments.
- CRISPRClustered regularly interspaced short palindromic repeats (CRISPR) is a prokaryotic adaptive immune response that provides immunity against foreign nucleic acids, such as viral DNA and bacterial plasmids, through the use of crRNAs (CRISPR RNAs) and associated Cas genes.